** Shares of Mayne Pharma Group MYX.AX soar 13.3% to A$5.30, their highest level since December 3, 2024
** Stock heads for a fourth consecutive session of gains, among top gainers in the ASX All Ordinaries index .AORD
** Speciality pharmaceutical firm says it expects 1H25 underlying EBITDA between A$30 million ($18.76 million) and A$32 million, up to four-fold jump from last year's A$8 million
** Revenue forecast between A$210 million and A$215 million, up to 14% growth
** Co expects to see continued growth in 2H25
** More than 112,000 shares change hands, vs the 30-day average of about 95,000 shares
** MYX up 6.8% this year, including day's moves
($1 = 1.5995 Australian dollars)
(Reporting by Sameer Manekar in Bengaluru)
((Sameer.Manekar@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。